Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer

Clin Cancer Res. 2005 Apr 1;11(7):2518-25. doi: 10.1158/1078-0432.CCR-04-1282.

Abstract

Purpose: Because the biological significance of constitutive nuclear factor-kappaB (NF-kappaB) activation in human gastric cancer is unclear, we undertook this study to clarify the regulatory mechanism of NF-kappaB activation and its clinical significance.

Experimental design: Immunohistochemistry for NF-kappaB/RelA was done on 290 human gastric carcinoma specimens placed on tissue array slides. The correlations between NF-kappaB activation and clinicopathologic features, prognosis, Akt activation, tumor suppressor gene expression, or Bcl-2 expression were analyzed. We also did luciferase reporter assay, Western blot analysis, and reverse transcription-PCR using the SNU-216 human gastric cancer cell line transduced with retroviral vectors containing constitutively active Akt or the NF-kappaB repressor mutant of IkappaBalpha.

Results: Nuclear expression of RelA was found in 18% of the gastric carcinomas and was higher in early-stage pathologic tumor-node-metastasis (P = 0.019). A negative correlation was observed between NF-kappaB activation and lymphatic invasion (P = 0.034) and a positive correlation between NF-kappaB activation and overall survival rate of gastric cancer patients (P = 0.0228). In addition, NF-kappaB activation was positively correlated with pAkt (P = 0.047), p16 (P = 0.004), adenomatous polyposis coli (P < 0.001), Smad4 (P = 0.002), and kangai 1 (P < 0.001) expression. An in vitro study showed that NF-kappaB activity in gastric cancer cells is controlled by and controls Akt.

Conclusions: NF-kappaB activation was frequently observed in early-stage gastric carcinoma and was significantly correlated with better prognosis and Akt activation. These findings suggest that NF-kappaB activation is a valuable prognostic variable in gastric carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Androstadienes / pharmacology
  • Blotting, Western
  • Cell Line, Tumor
  • Child
  • Child, Preschool
  • Chromones / pharmacology
  • Enzyme Activation
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genetic Vectors / genetics
  • Humans
  • Immunohistochemistry
  • Infant
  • Infant, Newborn
  • Luciferases / genetics
  • Luciferases / metabolism
  • Male
  • Middle Aged
  • Morpholines / pharmacology
  • NF-kappa B / analysis
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Neoplasm Staging
  • Prognosis
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism*
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • Retroviridae / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • Survival Analysis
  • Tissue Array Analysis
  • Transcription Factor RelA
  • Transfection
  • Tumor Suppressor Proteins / analysis
  • Wortmannin

Substances

  • Androstadienes
  • Chromones
  • Morpholines
  • NF-kappa B
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Messenger
  • Recombinant Fusion Proteins
  • Transcription Factor RelA
  • Tumor Suppressor Proteins
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Luciferases
  • AKT1 protein, human
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Wortmannin